Executive summary Despite substantial progress in reducing the global impact of many non-
communicable diseases, including heart disease and cancer, morbidity and mortality due to …

Disclosures: Dr. Labaki, ACP Contributing Author, reports nonfinancial support from
Pulmonx and personal fees from Konica Minolta outside the submitted work. Dr. Rosenberg …

Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic
and biological information in order to optimise the therapeutic benefit relative to the …

Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …

In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized
by an acute deterioration in respiratory symptoms, are fundamental events impacting …

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report
for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in …

Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …

Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic
subtypes have recently been described. Objectives: To use multiple datasets available …

Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and
mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent …

Chronic obstructive pulmonary disease (COPD) is a major global health problem that is
poorly treated by current therapies as it has proved difficult to treat the underlying …